avibactam sodium; ceftazidime - Profile

What are the generic drug sources for avibactam sodium; ceftazidime and what is the scope of patent protection?

Avibactam sodium; ceftazidime is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avibactam sodium; ceftazidime has one hundred and ninety-five patent family members in fifty-five countries.

Summary for avibactam sodium; ceftazidime

International Patents:	195
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for avibactam sodium; ceftazidime

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for avibactam sodium; ceftazidime

Dosage:

POWDER;IV (INFUSION)

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for AVIBACTAM SODIUM; CEFTAZIDIME

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVYCAZ	For Injection	avibactam sodium; ceftazidime	0.5 g/2 g per vial	206494	2	2024-02-26

US Patents and Regulatory Information for avibactam sodium; ceftazidime

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes			Y	Y
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes				Y
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes			Y

Expired US Patents for avibactam sodium; ceftazidime

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015

International Patents for avibactam sodium; ceftazidime

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1614	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
Argentina	031716	DERIVADOS DE 1-AZA Y 1,3- DIAZABICICLOETANOS Y ANALOGOS, UN PROCEDIMIENTO PARA SU PREPARACION, Y COMPOSICION FARMACEUTICA Y MEDICAMENTOS COMO ANTIBACTERIANOS
Austria	263768

Supplementary Protection Certificates for avibactam sodium; ceftazidime

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1480644	C01480644/01	Switzerland		PRODUCT NAME: AVIBACTAM + CEFTAZIDIM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66890 05.06.2019
1480644	132016000125850	Italy		PRODUCT NAME: MISCELA O ASSOCIAZIONE FARMACEUTICA CHE COMPRENDE COME PRINCIPI ATTIVI: (1) CEFTAZIDIMA O UN SUO SALE, E (2) AVIBACTAM O UN SUO SALE(ZAVICEFTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1109, 20160628
1480644	629	Finland

Investment Scenario, Market Dynamics, and Financial Trajectory for Avibactam Sodium and Ceftazidime

Last updated: February 3, 2026

Executive Summary

Avibactam sodium combined with ceftazidime is a potent antibiotic therapy targeting multidrug-resistant (MDR) Gram-negative pathogens. Given the escalating prevalence of antibiotic resistance and the limited pipeline of effective drugs, this combination is poised for significant market growth. Regulatory approvals, patent protections, and increasing antimicrobial resistance (AMR) drive market opportunities, especially within hospital and institutional settings. However, competitive dynamics, pricing pressures, and regulatory challenges could influence the financial trajectory.

Overview of the Drug Combination

Component	Description	Function
Avibactam Sodium	Beta-lactamase inhibitor	Inhibits class A, C, D beta-lactamases; restores ceftazidime efficacy
Ceftazidime	Third-generation cephalosporin antibiotic	Disrupts bacterial cell wall synthesis

Regulatory Status:

• Approved by FDA (2015) under Avycaz for complicated urinary tract infections, intra-abdominal infections, and pneumonia (including ventilator-associated pneumonia).
• Marketed in multiple countries, with ongoing pediatric and other infection indications.

---

What Is the Current Market Landscape?

Market Size and Growth Drivers

Indicator	Value / Trend	Source
Global antibacterial market (2023)	~$50 billion	[1]
Ceftazidime/avibactam market (2023)	~$1.2 billion	[2]
CAGR (2023-2028)	7.5%	[3]
Antimicrobial resistance (AMR) prevalence	Increasing, especially in MDR Gram-negatives	[4]

Growth Drivers:

• Rising incidence of multi-drug resistant pathogens, notably Klebsiella pneumoniae, Pseudomonas aeruginosa, and E. coli.
• Limited new antibiotics in late-stage development — need amplifies value.
• Regulatory incentivization, including Orphan Drug Designations, Fast Track, and Priority Review pathways, accelerating approvals.

Market Segmentation & Geographies

Region	Market Share (2023)	Growth Rate (2023-2028)	Key Factors
North America	45%	6.8%	High prevalence of healthcare-associated infections, established reimbursements
Europe	25%	8.0%	Stringent antibiotic stewardship programs, high AMR prevalence
Asia-Pacific	20%	10.5%	Growing healthcare expenditure, rising AMR, expanding hospital infrastructure
Rest of World	10%	9.0%	Increasing access, emerging markets, regulatory changes

---

Market Dynamics Influencing the Financial Trajectory

Key Factors Supporting Growth

1. Rising Antimicrobial Resistance (AMR)

AMR is projected to cause 10 million deaths annually by 2050 if not contained ([4]). The need for Last-line antibiotics like ceftazidime/avibactam justifies premium pricing and sustained demand.

2. Regulatory and Reimbursement Environment

Approval pathways, particularly in the U.S. and Europe, favor innovative antibiotics for resistant infections. Governments provide incentives like the 21st Century Cures Act (U.S.) and EU antibiotic strategies to promote development.

3. Patent Expiries and Market Exclusivity

• Patent expiry predictions for ceftazidime/avibactam are around 2030-2035, affecting pricing and revenue.
• Patent extensions via formulations, approvals for new indications, or combination strategies could prolong exclusivity.

4. Competitive Landscape

Competitors	Market Share	Key Products	Strengths
Merck (Zerbaxa)	Moderate	Simultaneous Carbapenem therapy	Broad-spectrum activity
Bristol-Myers Squibb (LisCvax)	Niche	Other beta-lactamase inhibitors	Ever-growing antibiotic pipeline
Emerging Alternatives	Niche	Novel beta-lactamase inhibitors	Novel mechanism of action, addressing resistance

Challenges

• Pricing Pressure: Governments and insurers seek cost-effective therapies, potentially limiting premium pricing.
• Development Risks: Clinical trial failures or post-market safety issues could affect revenue.
• Generic Entry: Possible if patents are challenged or expire, compressing margins.

---

Financial Trajectory Projections

Year	Estimated Revenue (USD millions)	Growth Rate	Assumptions
2023	~$1,200	N/A	Base case, moderate adoption
2024	~$1,300	8.3%	Increased adoption in hospital settings
2025	~$1,400	7.7%	Expanded indications, geographic expansion
2026	~$1,500	7.1%	Competitive positioning, price stabilization
2027	~$1,600	6.7%	Patent protections maintained, market stabilizes

Revenue Drivers:

• Adoption rate increases driven by antimicrobial stewardship policies.
• Expansion into new indications such as bloodstream infections.
• Uptake in emerging markets.

Cost Considerations:

• R&D investments for new indications or formulations.
• Compliance and regulatory costs.
• Manufacturing scale-up efficiencies.

---

Comparative Analysis: Ceftazidime/Avibactam vs Competitors

Parameter	Ceftazidime/Avibactam	Competitor A (e.g., Merck's Zerbaxa)	Competitor B (e.g., Merck's Zerbaxa)
Monthly Price (USD)	$7,000 - $10,000	Similar	Similar
Spectrum of Activity	Broad (including carbapenem-resistant strains)	Similar	Slightly narrower
Approved Indications	Complicated infections, intra-abdominal, pneumonia	Similar	Similar
Resistance Profile	Effective against MDR Gram-negatives	Similar	Slightly less active against certain carbapenemases
Patent Status	Valid until ~2030-2035	Similar	Similar

---

Deep Analysis: Opportunities and Risks

Opportunities	Risks
Growing demand due to AMR	Emergence of resistance to ceftazidime/avibactam
Expanding indications (e.g., pneumonia, bloodstream infections)	Development delays or setbacks
Market penetration in emerging markets	Pricing pressures and reimbursement hurdles
Novel delivery formats (e.g., oral, inhaled)	Regulatory hurdles for new formulations

---

FAQs

1. What factors most influence the market penetration of avibactam/ceftazidime?

Market penetration depends on the level of antimicrobial resistance, clinician adoption, regulatory approvals for new indications, and price competitiveness.

2. How does resistance development impact the financial outlook?

Emerging resistance, especially to ceftazidime/avibactam, could reduce effective patient population, pressuring revenues. Continuous surveillance and development of next-generation inhibitors are essential mitigation strategies.

3. What are the regulatory trends affecting this drug combination?

Regulatory agencies like the FDA and EMA incentivize development via fast-track approvals, orphan drug designation, and priority reviews but impose strict post-market surveillance requirements.

4. How significant is geographic expansion in revenue growth?

Extremely significant; emerging markets account for increasing proportions of sales, driven by rising antimicrobial resistance and expanding hospital infrastructure.

5. What are the main competitive differentiators?

Spectrum of activity against resistant pathogens, safety profile, formulation convenience, and cost-effectiveness.

---

Key Takeaways

• The global market for ceftazidime/avibactam is expected to grow at a CAGR of approximately 7.5% from 2023-2028, driven by rising antimicrobial resistance.
• Market opportunities are bolstered by increasing pathogen resistance, regulatory incentives, and expanding indications.
• Patent protections, market exclusivity, and competitive dynamics will significantly influence revenue streams up to and beyond 2030.
• Pricing pressures and the potential for emerging resistance represent key risks requiring strategic management.
• Geographical expansion, especially into Asia-Pacific markets, offers substantial growth opportunities.

---

References

[1] MarketsandMarkets, “Antibacterial Drugs Market,” 2023.
[2] IQVIA, “Ceftazidime/Avibactam Market Share and Sales Data,” 2023.
[3] GlobalData, “Antimicrobial Market Forecast,” 2023-2028.
[4] O'Neill, J., “Tackling drug-resistant infections globally,” The Review on Antimicrobial Resistance, 2016.

---

This comprehensive analysis aims to inform investment decisions in the ceftazidime/avibactam market, emphasizing current market forces, growth potential, and underlying risks.